Pronóstico de los pacientes operados de glioblastoma tras la protocolización de la resonancia magnética cerebral postquirúrgica precoz
DOI:
https://doi.org/10.23857/dc.v9i4.3618Palabras clave:
glioblastoma, tumor cerebral, radioterapia, quimioterapia, resonancia magnéticaResumen
El glioblastoma es el tumor cerebral primario más frecuente y agresivo. La cirugía resectiva seguido de radioterapia y quimioterapia se considera el tratamiento “gold-standar”. A pesar de ello, se trata de un tumor incurable, con un 100% donde el objetivo quirúrgico debe ser la resección completa comprobada mediante resonancia magnética cerebral post-quirúrgica. Sin embargo, no existe consenso en la literatura sobre lo que se considera resección completa y ningún estudio valora la posibilidad de reintervenir precozmente, en el mismo ingreso, a aquellos pacientes con restos tumorales en la resonancia magnética post-quirúrgica. La baja supervivencia de los pacientes no necesariamente se acompaña de un mal estado funcional. Aunque lamentablemente no existe una cura, existen tratamientos para el glioblastoma. Estos tratamientos alivian los síntomas y prolongan cómodamente su vida
Citas
Moton S, Elbanan M, Zinn PO, Colen RR. Imaging Genomics of Glioblastoma: Biology, Biomarkers, and Breakthroughs. Top Magn Reson Imaging. 2015;24(3):155-63.
Ray SK, editor. Glioblastoma: molecular mechanisms of pathogenesis and current therapeutic strategies. Dordrecht?; New York: Springer; 2010. 431 p.
Karsy M, Gelbman M, Shah P, Balumbu O, Moy F, Arslan E. Established and emerging variants of glioblastoma multiforme: review of morphological and molecular features. Folia Neuropathol. 2012;50(4):301-21.
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. NeuroOncology. 2021;23(8):1231-51.
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803-20.
Nakazato Y. [The 4th Edition of WHO Classification of Tumours of the Central Nervous System published in 2007]. No Shinkei Geka. 2008;36(6):473-91.
Masui K, Mischel PS, Reifenberger G. Molecular classification of gliomas. Handb Clin Neurol. 2016;134:97-120.
Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. The Lancet Oncology. 2017;18(6):e315-29.
Balañá C, Alonso M, Hernandez A, Perez-Segura P, Pineda E, Ramos A, et al. SEOM clinical guidelines for anaplastic gliomas (2017). Clinical and Translational Oncology. 2018;20(1):16-21.
Moritani T, Ekholm S, Westesson P-L. Diffusion-weighted MR imaging of the brain: with 11 tables. Berlin: Springer; 2005. 229 p.
Pineda E, Martinez-Garcia M, Estival A, Gil-Gil M, Del Barco S, Gallego O, et al. Longterm survivors (LTS) in glioblastoma (GBM) patients (pts) homogeneously treated with the Stupp regimen, clinical and molecular characteristics (MGMT and IDH1 status). Initial results from the GLIOCAT study. Annals of Oncology [Internet]. 2016 ;27(suppl_6). 347p. 156
Anil R, Colen RR. Imaging Genomics in Glioblastoma Multiforme: A Predictive Tool for Patients Prognosis, Survival, and Outcome. Magn Reson Imaging Clin N Am. 2016;24(4):731-40.
Sawaya R, Hammoud M, Schoppa D, Hess KR, Wu SZ, Shi WM, et al. Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery. 1998;42(5):1044-55.
Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. Journal of Neurosurgery. 2001;95(2):190-8.
Shergalis A, Bankhead A, Luesakul U, Muangsin N, Neamati N. Current Challenges and Opportunities in Treating Glioblastoma. Pharmacol Rev. 2018;70(3):412-45.
Roger Stupp, M.D., Warren P. Mason, M.D., Martin J. van den Bent, M.D., Michael Weller, M.D, et al. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. The New England Journal of Medicine. 2005;352: 987-96
Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9(3):157-73.
Yoon S-J, Shim J-K, Chang JH, Moon JH, Roh T-H, Sung KS, et al. Tumor Mesenchymal Stem-Like Cell as a Prognostic Marker in Primary Glioblastoma. Stem Cells Int. 2016;2016:6756983. 7p
Shahar T, Rozovski U, Hess KR, Hossain A, Gumin J, Gao F, et al. Percentage of mesenchymal stem cells in high-grade glioma tumor samples correlates with patient survival. Neuro-Oncology. 2016; 19(5): 660-68.
Karsy M, Neil JA, Guan J, Mahan MA, Mark MA, Colman H, et al. A practical review of prognostic correlations of molecular biomarkers in glioblastoma. Neurosurg Focus. 2015;38(3):E4.
Siegal T. Clinical impact of molecular biomarkers in gliomas. Journal of Clinical Neuroscience. 2015;22(3):437-44.
Ohno M, Narita Y, Miyakita Y, Matsushita Y, Arita H, Yonezawa M, et al. Glioblastomas with IDH1/2 mutations have a short clinical history and have a favorable clinical outcome. Japanese Journal of Clinical Oncology. 2016;46(1):31-9.
Beiko J, Suki D, Hess KR, Fox BD, Cheung V, Cabral M, et al. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro-oncology. 2014;16(1):81-91.
Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. The Lancet Oncology. 2017;18(10):1373-85. 8. Referencias 157
Schuster J, Lai RK, Recht LD, Reardon DA, Paleologos NA, Groves MD, et al. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro-Oncology. 2015;17(6):854-61.
Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699-708.
Hong EK, Choi SH, Shin DJ, Jo SW, Yoo R-E, Kang KM, et al. Radiogenomics correlation between MR imaging features and major genetic profiles in glioblastoma. European Radiology [Internet]. 2018; 20 : 120-27
Zinn PO, Mahajan B, Majadan B, Sathyan P, Singh SK, Majumder S, et al. Radiogenomic mapping of edema/cellular invasion MRI-phenotypes in glioblastoma multiforme. PLoS ONE. 2011;6(10):e25451.
Zinn PO, Sathyan P, Mahajan B, Bruyere J, Hegi M, Majumder S, et al. A novel volumeage-KPS (VAK) glioblastoma classification identifies a prognostic cognate microRNAgene signature. PLoS ONE. 2012;7(8):e41522.
Gevaert O, Mitchell LA, Achrol AS, Xu J, Echegaray S, Steinberg GK, et al. Glioblastoma Multiforme: Exploratory Radiogenomic Analysis by Using Quantitative Image Features. Radiology. 2015;276(1):313.
Ellingson BM. Radiogenomics and Imaging Phenotypes in Glioblastoma: Novel Observations and Correlation with Molecular Characteristics. Current Neurology and Neuroscience Reports [Internet]. 2015;15(1). 459-64
Wang K, Wang Y, Fan X, Wang J, Li G, Ma J, et al. Radiological features combined with IDH1 status for predicting the survival outcome of glioblastoma patients. Neurooncology. 2016;18(4):589-97.
Naeini KM, Pope WB, Cloughesy TF, Harris RJ, Lai A, Eskin A, et al. Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images. Neuro-oncology. 2013;15(5):626-34.
Hirai T, Murakami R, Nakamura H, Kitajima M, Fukuoka H, Sasao A, et al. Prognostic value of perfusion MR imaging of high-grade astrocytomas: long-term follow-up study. AJNR Am J Neuroradiol. 2008;29(8):1505-10.
Romano A, Pasquini L, Di Napoli A, Tavanti F, Boellis A, Rossi Espagnet MC, et al. Prediction of survival in patients affected by glioblastoma: histogram analysis of perfusion MRI. Journal of Neuro-Oncology [Internet]. 2018
Bag AK, Cezayirli PC, Davenport JJ, Gaddikeri S, Fathallah-Shaykh HM, Cantor A, et al. Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters. Journal of Neuro-Oncology. 2014;120(2):361-70.
Luca DSD, Stoisa D, Mondello E, Vietti J, Casas G, Florenzano N, et al. UTILIDAD DEL MAPA ADC EN LA CARACTERIZACIÓN DE TUMORES ENCEFÁLICOS. 2004;68:7.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2023 Bustamante Chica Eddy Anthony, Aguilar Santana Andrea Nicole, Busquets Insuaste María Isabel, Arévalo Rodríguez Dalton Arturo
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Authors retain copyright and guarantee the Journal the right to be the first publication of the work. These are covered by a Creative Commons (CC BY-NC-ND 4.0) license that allows others to share the work with an acknowledgment of the work authorship and the initial publication in this journal.
